Day three of bionano's next-generation cytogenomics symposium: saphyr provides complete structural variation analysis in solid tumors, enables discovery of novel diagnostic markers and drug targets

San diego, jan. 14, 2021 (globe newswire) -- bionano genomics, inc. (nasdaq: bngo) announced that day three of its five-day next-generation cytogenomics symposium featured six saphyr users presenting their results and experiences using the saphyr® system for optical genome mapping (ogm) to analyze solid tumor genomes. the presentations by scientists and clinicians from leading hospitals and medical research institutions in europe and the us discussed results on a variety of solid tumors such as cancers of the head and neck, brain, breast, liver, and the eye. all six studies showed that saphyr enables for the first time a complete and clear picture of structural variation in the genome and provides opportunity for the discovery of novel cancer drivers, therapeutic targets, and prognostic markers, something which has not been possible to date with next-generation sequencing (ngs) and array platforms.
BNGO Ratings Summary
BNGO Quant Ranking